Bevaludine for injection of hausen Pharmaceutical Co., Ltd. is about to obtain production approval document to break the monopoly of xinlitai

According to the website of the State Food and Drug Administration (CFDA) on May 14, the status of bevaludine for injection applied for production by Jiangsu Haosen Pharmaceutical Co., Ltd has changed into "certificate preparation completed - issued approval document" The company is expected to obtain production approval document recently, and the product will break the monopoly position of xinlitai in the domestic market after being listed Bevaludine for injection (teganine) is a new and exclusive product of xinlitai at the end of 2011 It is also a strong product of xinlitai after its flagship product "Taijia", which greatly enriches the company's cardiovascular specialty product echelon As a high-end generic drug for surgery, xinlitai estimates that the annual sales of the product will reach 300-500 million in the future But at present, in the situation that the provincial bidding has not yet started on a large scale, the sales volume of teganin is not optimistic, and it is anxiously waiting for the opening of the bidding curtain In the case that the product volume is not good and there are no loyal customers, the second model drug companies will share some of the market In this regard, xinlitai, who has paid early attention to the arrival of competitors, once said that it is normal for products to have competitors When there are only two companies producing products, the market will have a benign competition, hoping that there will be no competitive situation CFDA shows that at present, there are more than 10 domestic enterprises applying for bevaludine, and the competition pattern of bevaludine in the future is more intense.